High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive

Diabetes, Obesity and Metabolism

Volumn 13, Issue 8, 2011, Pages 759-764

  Ferrannini, E ^a   Betteridge, D J ^b   Dormandy, J A ^c   Charbonnel, B ^d   Wilcox, R G ^e   Spanheimer, R ^f   Erdmann, E ^g   Defronzo, R A ^h   Laakso, M ⁱ  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d Clinique d'Endocrinologie Hotel Dieu CHU de Nantes   (France)

^e QUEEN S MEDICAL CENTRE   (United Kingdom)

^f Pharmaceuticals North America Inc   (United States)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^h Mays Cancer Center at UT Health San Antonio   (United States)

ⁱ KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cardiovascular disease; Thiazolidinediones; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG USE; HEART INFARCTION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE; VITAL SIGN;

EID: 79959440590     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01404.x     Document Type: Article

References (27)

1. Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-431.
2. Stettler C, Allemann S, Jüni P et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006; 152: 27-38.
3. Leibel B. An analysis of the UGDP. Can Med Assoc J 1971; 105: 292-294.
4. The UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
5. Gerstein HC, Miller ME, Byington RP et al. Action to control cardiovascular risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
6. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
7. Duckworth W, Abraira C, Moritz T et al. Intensive glucose control and complications in American veteran with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
8. Dormandy JA, Charbonnel B, Eckland EJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes: a randomized trial of pioglitazone. The PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events). Lancet 2005; 366: 1279-1289.
9. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil AW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
10. Nathan DM, Cleary PA, Backlund JY et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
11. Gaede P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
12. Holman RR, Retnakaran R, Farmer A, Stevens R. PROactive study. Lancet 2006; 367: 25-26.
13. van Dieren S, Peelen LM, Nöthlings U et al. External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes. Diabetologia 2011; 54: 264-270.
14. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
15. Barter P, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-1310.
16. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-1255.
17. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512-3517.
18. Davidson M, Meyer PM, Haffner SM et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 2008; 114: 2132-2130.
19. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007; 356: 2522-2524.
20. Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-1573.
21. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188.
22. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
23. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.
24. Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554.
25. Deeg MA, Buse JB, Goldberg RB et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007; 30: 2458-2464.
26. Beysen C, Murphy EJ, Nagaraja H et al. A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes. J Lipid Res 2008; 49: 2657-2663.
27. Robinson JG. Should we use PPAR agonists to reduce cardiovascular risk? PPAR Res 2008; 2008: 891425.